Ipilimumab monotherapy in a phase III trial in unresectable stage III and IV melanoma patients had the best overall response rate (10.9%) compared to ipilimumab plus glycoprotein 100 (gp100) vaccine (5.7%) or gp100 monotherapy (1.5%). Here, PMEL is linked to melanoma.